title: Management of operable invasive breast cancer in women over the age of 70: long-term results of a large-scale single-institution experience.
abstract: BACKGROUND
  The treatment of choice for elderly women with breast cancer remains controversial. This retrospective analysis of a cohort from a single institution was designed to evaluate whether such patients are really undertreated because of their age and to reappraise their usual management.
  
  
  METHODS
  The characteristics of 538 patients aged > or = 70 years with operable breast cancer, treated between 1995 and 1999, were retrospectively analyzed comparing patients aged 70 to 75 years (group I, n = 288), 75 to 80 years (group II, n = 156), and > or = 80 years (group III, n = 94). Cause-specific survival, distant recurrence-free interval, and local control were estimated by the Kaplan-Meier method and compared by log rank test. Multivariate analysis used Cox regression.
  
  
  RESULTS
  In group III, tumors were more frequently T2 than T1 (P < 0.0001) and estrogen receptor negative (P = 0.045) than in groups I and II. Surgery was performed in 94.6% of patients, breast-conserving in 72.1% (62% in group III; P = 0.0015) with axillary dissection in 89.2% (77% in group III; P = 0.0015); 100% received radiotherapy after lumpectomy (hypofractionated in 63% of group III; P < 0.0001). Adjuvant hormone therapy and chemotherapy were administered to 57 and 3.7% of patients, respectively. At 7 years, no difference in the three groups was observed for cause-specific survival (91% for group I, 89% for group II, 86% for group III) distant recurrence-free interval, and local control (>90%).
  
  
  CONCLUSIONS
  Elderly patients with operable breast cancer who are completely and correctly treated with realistic treatment options that are based on surgery and adjuvant radiotherapy have a similar chance of being cured as younger patients.
authors.affiliation: Department of Surgery, Institut Curie, Paris, France. fatima.laki@curie.net
authors.forename: Fatima
authors.initials: F
authors.lastname: Laki
authors.forename: Youlia M
authors.initials: YM
authors.lastname: Kirova
authors.forename: Alexia
authors.initials: A
authors.lastname: Savignoni
authors.forename: Francois
authors.initials: F
authors.lastname: Campana
authors.forename: Beatrice
authors.initials: B
authors.lastname: Levu
authors.forename: Marc
authors.initials: M
authors.lastname: Estève
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sigal-Zafrani
authors.forename: Thierry
authors.initials: T
authors.lastname: Dorval
authors.forename: Bernard
authors.initials: B
authors.lastname: Asselain
authors.forename: Remy J
authors.initials: RJ
authors.lastname: Salmon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D016330:Frail Elderly; D005602:France; D006785:Hospitals, University; D006801:Humans; D053208:Kaplan-Meier Estimate; D008197:Lymph Node Excision; D008408:Mastectomy / Q000379:methods / Q000401:mortality; D015412:Mastectomy, Segmental; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016896:Treatment Outcome